Randomized Trialhigh evidence
Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.
Journal of the American College of Cardiology·June 2, 2026·PMID 42233552
Why it mattersClinicians managing patients with type 2 diabetes and CKD can expect kidney and survival benefits from semaglutide regardless of a patient's cardiovascular history, supporting its use as a foundational therapy in this high-risk population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled